All In Biotech

Drug Trial Radar · NCT07534592

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

An Open-label, Fixed-sequence Study to Assess the Effect of Elecoglipron on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Actual

Start

Apr 16, 2026

Primary completion

Jan 25, 2027

Study completion Jan 25, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Apr 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.

Conditions

  • Healthy Participants

Interventions

  • ElecoglipronDrug

    Elecoglipron will be administered as oral tablet.

  • AtorvastatinDrug

    Atorvastatin will be administered as oral tablet.

  • RosuvastatinDrug

    Rosuvastatin will be administered as oral tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under concentration-time curve from time 0 to infinity (AUCinf) of atorvastatinTime frame: Group 1: Day 1 to Day 71
  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of atorvastatinTime frame: Group 1: Day 1 to Day 71
  3. Maximum observed drug concentration (Cmax) of atorvastatinTime frame: Group 1: Day 1 to Day 71
  4. AUCinf of rosuvastatinTime frame: Group 2: Day 1 to Day 76
  5. AUClast of rosuvastatinTime frame: Group 2: Day 1 to Day 76
  6. Cmax of rosuvastatinTime frame: Group 2: Day 1 to Day 76
  7. Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on AUCinf (R AUCinf) of atorvastatinTime frame: Group 1: Day 1 to Day 71
  8. Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on AUClast (R AUClast) of atorvastatinTime frame: Group 1: Day 1 to Day 71
  9. Ratio of Atorvastatin (Atorvastatin + elecoglipron) to Atorvastatin (alone) based on Cmax (R Cmax) of atorvastatinTime frame: Group 1: Day 1 to Day 71
  10. Terminal elimination half-life (t1/2λz) of atorvastatinTime frame: Group 1: Day 1 to Day 71
  11. Terminal rate constant (λz) of atorvastatinTime frame: Group 1: Day 1 to Day 71
  12. Time to reach maximum observed concentration (tmax) of atorvastatinTime frame: Group 1: Day 1 to Day 71
  13. Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on AUCinf (R AUCinf) of rosuvastatinTime frame: Group 2: Day 1 to Day 76
  14. Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on AUClast (R AUClast) of rosuvastatinTime frame: Group 2: Day 1 to Day 76
  15. Ratio of Rosuvastatin (Rosuvastatin + elecoglipron) to Rosuvastatin (alone) based on Cmax (R Cmax) of rosuvastatinTime frame: Group 2: Day 1 to Day 76
  16. t1/2λz of rosuvastatinTime frame: Group 2: Day 1 to Day 76
  17. λz of rosuvastatinTime frame: Group 2: Day 1 to Day 76
  18. tmax of rosuvastatinTime frame: Group 2: Day 1 to Day 76

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California

  • Research Site

    Brooklyn, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.